I do believe that if the data from the Merck combo trial is excellent then the sky is the limit with regards to share price. A parabolic share spike could be in the cards for Oncosec. That happens all the time with speculative biotech companies. I also believe that good results will lead to other combo trials with Merck and possibly other partnerships with other companies who might be interested in a buyout of Oncosec in the future if Merck is not the buyer. Merck was willing to fork out $8 billion dollars for Cubist so who knows what an Oncosec buyout could bring in the future. It could be huge. Time will tell. Good luck to all investors here and the many lives that would be saved by innovative science brought forth by Oncosec and Merck.
News 
Market Data 
Discover 
